Although a successful vaccine against HBV has been implemented in 184 countries, eradication of hepatitis B virus (HBV) is still not on the horizon. There are over 240 million chronic carriers of HBV globally. The risk of developing chronic hepatitis ranges from >90% in newborns of hepatitis Be antigen (HBeAg)-positive mothers, 25%-35% in children under 5 years of age and <5% in adults. HBeAg, a non-particulate viral protein, is a marker of HBV replication. This is the only HBV antigen to cross the placenta, leading to specific unresponsiveness of helper T cells to the capsid protein and HBeAg in newborns. HBeAg is tolerated in utero and acts as a tolerogen after birth. Perinatal transmission is frequent when mothers are HBeAg-positive, whereas it occurs less frequently when mothers are HBeAg-negative. Sequence heterogeneity is a feature of HBV. Based on an intergroup divergence >7.5% across the complete genome, HBV is classified phylogenetically into at least nine genotypes. With between~4% and 8% intergroup nucleotide divergence, genotypes A-D, F, H and I are classified further into subgenotypes. HBV genotypes/subgenotypes may have distinct geographical distribution and can develop different mutations in the regions of the HBV genome that code for HBeAg. These differences can be related to the role of HBV genotypes to the natural history of infection and mode of transmission. Thus genotypes/subgenotypes of HBV can be responsible for the different natural history of infection and modes of transmission in children, found in various regions of the world, where different genotypes/subgenotypes prevail. © 2016 The Authors Reviews in Medical Virology Published by John Wiley & Sons, Ltd. 
GLOBAL EPIDEMIOLOGY AND PATHOGENESIS OF HEPATITIS B VIRUS (HBV) INFECTION
Two of the 7.3 billion of the world's population have been exposed the hepatitis B virus (HBV). It is estimated that 240 million individuals are currently chronically infected with this virus [1] . Twenty to thirty percent of the chronic carriers of HBV will develop complications including acute liver failure, hepatic decompensation, cirrhosis and hepatocellular carcinoma (HCC). Annually approximately 786 000 people die as a result of complications caused by chronic HBV infection. These deaths are ranked 15 th in the Global Burden of Disease (GBD) 2010 [2] and account for 50% and 33% of deaths as a result of HCC and cirrhosis, respectively [2] .
With the exception of Ecuador, Peru, Bolivia, and southern eastern Asia, Indonesia and East Timor, the prevalence of HBV infection in children (5 to 9 years) coincides with that in adults (19 to 49 years) ( Figure 1 ) [3, 4] . In these south American countries, the prevalence in children is higher than in adults, whereas the opposite is true in the Asian countries, except for Indonesia and East Timor, where it is higher [3] . Between 1990 and 2005 there was an increase in chronic HBV infections among younger age groups in southern-eastern sub-Saharan Africa, whereas in central subSaharan Africa there was a corresponding decrease [3] . In central and eastern Europe, the most affected age group was younger than 9 years old, with a minimal decrease between 1990 and 2005. Between 1990 and 2005, the strongest reduction in prevalence of HBsAg in children was recorded in south east Asia [3] . This decrease is attributable to the introduction of effective vaccination programs.
MOLECULAR BIOLOGY OF HBV AND HBeAG
HBV, the smallest DNA virus infecting man, belongs to the family Hepadnaviridae and is the prototype member of the genus Orthohepadnavirus. HBV has a partially double-stranded, circular DNA genome of~3 200 base pairs. This compact genome contains four partly or completely overlapping open reading frames (ORFs): precore/core (preC/C) that encodes the e antigen (HBeAg) and core protein (HBcAg); P for polymerase (reverse transcriptase), PreS1/PreS2/S for surface proteins (three forms of HBsAg, small (S), middle (M) and large (L)) and X for a transcriptional trans-activator protein [5] (Figure 2 ). The four open reading frames (ORFs) are shown: precore/core (preC/C) that encodes the e antigen (HBeAg) and core protein (HBcAg); P for polymerase (reverse transcriptase), PreS1/PreS2/S for surface proteins (three forms of HBsAg, small (S), middle (M) and large (L)) and X for a transcriptional trans-activator protein HBV replicates by reverse transcription of the pregenomic RNA (pgRNA), a 3.5 kb RNA intermediate [6] , which is transcribed, by the cellular RNA polymerase II, from the covalently closed circular form of HBV DNA in the hepatocyte nucleus [7] . In order to be reverse transcribed the pgRNA has to be folded into a secondary structure, known as the encapsidation signal (ε) [8] (reviewed in [9] ) and enclosed in the viral capsid, which is comprised of HBcAg. Anti-HBc antibodies are a measure of exposure to HBV but not necessarily immunity. Surrounding the capsid is an envelope made up of lipid membrane from the host, in which are embedded HBsAg proteins coded by the virus (Figure 3 ). The presence of anti-HBs signals immunity to HBV. In addition to the structural proteins, HBc and HBs antigens, HBV codes for two non-particulate proteins X (a transcriptional transactivator protein) and HBeAg [10] .
HBeAg is encoded by the preC/C ORF (1814 -2452/2488 from the EcoRI site, [11] ) and the basic core promoter (BCP) of HBV controls the transcription of the preC/C region [12,13] (reviewed in [14] ). The preC/C fusion protein, which is the precursor of HBeAg has a signal peptide on its amino end that targets it to the endoplasmic reticulum, where it is post-translationally modified [15] . The amino end is truncated at amino acid 19, whereas the carboxyl end is cleaved at variable sites. The mature HBeAg is secreted and is soluble in serum [16] (Figure 4) .
Although HBeAg is not required for viral assembly or replication it is conserved in all orthohepadnaviruses [17] and is important for natural infection in vivo [18] . Clinically, HBeAg is an index of viral replication, infectivity, inflammation, severity of disease and response to antiviral therapy. Seroconversion from HBeAg-positive to HBeAg-negative/anti-HBeAg-positive phase usually heralds resolution of infection [19] . However, the emergence of BCP and precore mutations can lead to HBeAg-negative infection, where viral replication and inflammation remain high. While the exact function of HBeAg has not been elucidated, it has been shown to be an immunoregulatory protein, which acts as a tolerogen [20] and an immunogen [21] , triggers an interleukin-1 response [22] and regulates toll-like receptor 2 (TLR-2) expression [23] . Immune regulation mediated by HBeAg may lead to chronicity and persistence following perinatal infection and in adults prevent severe liver injury as result of infection [18] . Chronic infection will result following perinatal transmission from HBeAg-positive mothers. On the other hand, transmission from HBeAg-negative mothers can result in acute hepatitis or acute liver failure [24] . In addition to being an important milestone of chronic HBV infection, HBeAg status (HBeAg-positivity and thus the risk of developing chronic hepatitis is:
• >90% in newborns of HBeAg-positive mothers [26, 27] . This is probably because of the immature immune system of the infant [28] and/or the foetus developing immune tolerance as a result of the transplacental crossing of either the virion or HBeAg, the only HBV antigen that can cross the placenta [18] . Transplacental crossing of HBeAg induces a specific unresponsiveness of helper T cells to both HBcAg and HBeAg [29] .
• 25%-35% in infants and children under the age of 5 years • 6% in children 5 to 15 years • <5% in adults [30] Differentiated by the level of viral replication and the host immune response, chronic HBV infection acquired perinatally or in early infancy is broadly divided into four phases in children ( Figure 5 ):
(1) The high replicative, low inflammatory phase (previously immune tolerant phase) [47] [48] [49] . This seroconversion rate is lower than that seen in individuals infected as adolescents or in adulthood [50] . More than 90% of patients, infected 289 HBV genotypes and HBeAg in pediatrics in childhood, remain HBsAg carriers in adulthood [50] . Acquisition of infection horizontally is associated with a higher HBsAg clearance rate, as is being born to a HBsAg-negative mother [46] . The levels of anti-HBs after loss of HBsAg are higher in children born to HBsAg-positive mothers compared to those born to HBsAg-negative mothers. [46] Albeit that liver damage is minimal in the majority of children, some can manifest with mild inflammation and acute hepatitis [49] , as well serious complications of HBV infection, including cirrhosis and HCC, 2 to 7 years after infection [44] . Risk factors for early HCC development include cirrhosis and HBeAg seroconversion before 3 years [44] . Normal ALT levels and anti-HBeAg seroconversion are no guarantee against cirrhosis and HCC, especially in untreated individuals [44] . In a European study, children developed HBeAgnegative chronic hepatitis and/or HCC after an average 5-year follow-up [50] . It is possible that there are different mechanisms for the development of HCC in adults and children. The former require higher viral loads and liver inflammation, whereas integration of HBV in the human genome may trigger HCC in children [51] .
Although genetic and environmental factors, including socioeconomic and hygiene levels, can play a role in the natural history of HBV infection and the development of advanced liver disease, it is becoming increasingly evident that the genotypes/ subgenotypes of HBV and specific mutations can play a leading role [25, 52] .
GENOTYPES AND SUBGENOTYPES OF HBV
Sequence heterogeneity is a feature of HBV, because the viral encoded polymerase lacks proofreading ability. To date, based on an intergroup divergence of greater than 7.5% across the complete genome, HBV has been classified phylogenetically into 9 genotypes, A to I [11, [53] [54] [55] , with a putative 10 th genotype, "J", isolated from a single individual [56] , which is a recombinant of genotype C and gibbon HBV in the S region [57] . With between~4% and 8% intergroup nucleotide difference across the complete genome and good bootstrap support, genotypes A -D, F, H and I are classified further into at least 35 subgenotypes [55] . The genotypes differ in genome length, the size of ORFs and the proteins translated [11] , as well as the development of various mutations [52] . Based on HBsAg heterogeneity [11] , nine serological subtypes, ayw1, ayw2, ayw3, ayw4, ayr, adw2, adw4, adwq, adr and adrq, have been identified. A broad, highly statistically significant correlation exists between serological subtypes and genotypes: adw is associated with genotypes A, B, F, G and H, adr with C and ayw with D and E [58] but many exceptions exist ( Figure 6 ).
The genotype of HBV can influence the outcome of HBV infection in children because it can affect the frequency of HBeAg-positivity, the age at which HBeAg loss occurs and the mode of transmission. Therefore the natural history of HBV infection can differ in different geographical regions ( [52, 55, 59, 60] and references cited therein).
GEOGRAPHIC DISTRIBUTION OF GENOTYPES
Globally and locally the various genotypes, and in some cases the subgenotypes, have distinct geographical distributions [11, 55] (Figure 7 ). Genotype A is found in Africa, Europe and the Americas whereas genotypes B and C predominate in south east Asia. Although genotype D is distributed in all continents and is referred to as the cosmopolitan genotype, its subgenotypes can be geographically distributed [61] . Genotype E is confined to western Africa and distributed to other regions of the world following emigration from Africa. Central and South America are the regions where genotype F and H originate. Although genotype G was originally described in Georgia, United States of America, it has been isolated in the United Kingdom, Germany and Italy. Subgenotype A1 predominates in Africa and in regions outside Africa where there has been mass migration from Africa [62] . The subgenotype of A found outside Africa is subgenotype A2. Subgenotype B1 prevails in Japan and B2 in south east Asia, with B5 (formerly B6) found in Alaska. Thus in the two regions of the world where HBV occurs at high endemicity different genotypes prevail. Subgenotype A1, genotypes D and E circulate in sub-Saharan Africa and genotypes B and C in south eastern Asia.
RECOMBINATION BETWEEN GENOTYPES
In geographical regions where a number of genotypes co-circulate, recombination between genotypes can occur, and this provides a mechanism of variation within individuals and in the population in general [11] . Genotype A and D recombinants have been found in Africa [63] ,
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A. Kramvis whereas in Asia genotype B/C recombinants occur [64, 65] . Tibet has a 26.2% HBV carrier rate, and 96% of the isolates sequenced were C/D recombinants [66] . The breakpoints occurred most frequently in the BCP/PC region, with breakpoints found in the small S and core regions [67, 68] . The recombination may provide a selection advantage to the viral strains, and the recombinants may become the [60] .
GENOTYPING AND SUBGENOTYPING METHODS
Although the HBV S gene sequence is generally adequate to assign genotypes [58] , the complete sequence of the HBV genome provides additional information with respect to phylogenetic relatedness [70, 71] . Moreover, recombinants may not be identified when using a single region of the HBV genome for phylogenetic analysis. Nevertheless, although complete genome sequencing, followed by phylogenetic analysis, provides the gold standard for genotyping, it does not allow for rapid and direct analysis on a large scale basis [11] and requires expertise and thus capacity development in computer processing coupled with phylogenetic analyses. In order to expedite and facilitate genotyping a number of methods have been developed [11, 72, 73] . A number of commercially available assays are available, for example, genotype-specific probes assay (Smitest HBV Genotyping Kit, Genome Science, Fukushima, Japan), reverse hybridization of PCR products to probes on nitrocellulose strips (the line probe assay, LiPa ™ , Innogenetic Inc, Gent, Belgium) and enzyme linked immunosorbent assay (ELISA) (HBV Genotype EIA, Institute of Immunology, Tokyo, Japan). Each one has its advantages and disadvantages [11, 72, 73] , which should be taken into account, when selecting the genotyping method appropriate for a particular study or application [74] .
THE EFFECT OF GENOTYPE/SUBGENOTYPE ON HBeAG EXPRESSION
HBeAg, discovered in 1972 [10] , has been the classical marker for HBV replication, and its presence for longer than 10 weeks can herald the transition to chronic infection [35] . Transition from the immune clearance phase to the HBeAg-negative chronic hepatitis phase is accompanied by HBeAg seroconversion, the movement of HBcAg from the nucleus to the cytoplasm [75] and an increase in the frequency of HBV strains with BCP and precore mutations [76, 77] . Mutations in the BCP and preC can influence the expression of HBeAg at the transcriptional, translational and post-translational levels. Transcription of the preC mRNA is affected by A1762T/G1764A [78] . At the translational level, mutations in the Kozak sequence preceding the preC start codon (1814 from the EcoRI site) can affect the expression of HBeAg by a leaky scanning mechanism [79] whereas G1896A introduces a stop codon that leads to the truncation of the HBeAg precursor [80] . The G1862T mutation in the preC affects expression at a post-translational level [81] .
The propensity to develop precore mutations can be influenced by the HBV genotype or subgenotype. As described previously, the preC/C region is transcribed into the precore mRNA that is translated into the precursor of HBeAg (Figure 4) . The preC/C region also overlaps with the region that is transcribed into the pgRNA, which is the RNA intermediate of HBV replication. In order to be successfully encapsidated, the pgRNA has to be folded into a secondary structure known as ε, which has to be stable, for viral replication to proceed. The sequence of the preC/C region differs in the different genotypes, and in some cases, the subgenotypes [17] . For example, 1858C in the preC/C region is positively associated with genotypes A, F and H and 1858T with genotypes B, D and E [58] . Subgenotype C2 has 1858T as opposed to C1 that has 1858C and F1/F4 can be differentiated from F2/F3 by having 1858T instead of 1858C [58] . 1888A is positively associated with subgenotype A1 [58] .
Subgenotypes A1, A2 and genotype D, which circulate in southern Africa, will be used to explain and illustrate how nucleotide differences can influence HBeAg expression. Comparison of the sequences of BCP/PreC region of the different (sub) genotypes A1, A2 and D reveals variations that can account for the differences in HBeAg expression ( Figure 8A) . Furthermore, the frequency of these mutations/variations also differs between these (sub) genotypes ( Figure 8B) [82]. The presence of 1858C in genotype A precludes the G1896A mutation found in genotype D because
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A. Kramvis the presence of 1858C and 1896A would destabilize ε and compromise viral replication ( Figure 8C ) [83, 84] . 1896A converts the codon for tryptophan to a stop codon, leading to the truncation of the HBeAg precursor and abrogation of HBeAg expression ( Figure 9A ) [80] . This is the mutation that prevails in isolates obtained from HBeAg-negative individuals infected with genotype D. The only mutations that can influence HBeAg expression in strains isolated from individuals infected with subgenotype A2, which has 1858C, are 1762T/1764A ( Figure 9B ). On the other hand, in addition to the 1762T/1764A, subgenotype A1 strains, which also have 1858C, can develop mutations in the Kozak sequence (1809-1812) and the G1862T ( Figure 9C) [85], accounting for the higher frequency of HBeAg-negativity observed in individuals infected with this subgenotype. In a case control study, comparing individuals infected with subgenotypes A1, A2 and genotype D, respectively, it was shown, regardless of the age group, the frequency of HBeAg-positivity was lower in individuals infected with subgenotype A1 compared to the other (sub) genotypes [86] . This difference reached statistical significance in individuals younger than 30 years of age [86] . As a result of the distinct geographic distributions of the (sub) genotypes globally, the . In 1990, the highest prevalence was seen in girls aged 0 to 9 years (55%-91%) and decreased to 12%-16% in the 60 -69 year age group. In the childbearing age group of 20 -29 years the levels ranged from 30% to 43%. The highest levels in all age groups were found in Oceania (91% in the 0 -9 age group), with the lowest levels in southern and western sub-Saharan Africa (55%-62%) [91] . Although the trends were similar in 2005, there were some changes. The prevalence dropped most dramatically in the birth to 9 year olds in Oceania (~23%) with minimal or no decrease in southern (7%) and western (0.2%) subSaharan Africa, respectively. The reduction evident in some geographical regions was a result of the good implementation of successful vaccination programs [91] .
The expression of HBeAg is one of the major factors influencing the frequency and mode of transmission of HBV [92] .
FREQUENCY OF TRANSMISSION
In a study carried out in Iran [93] , where a datamining approach was used, the overall transmission rate was 15.7% (5.4% and 27.3% for male and female index cases, respectively). The frequency of transmission was more than double for HBeAgpositive females (49%) compared to HBeAgnegative females (23.4%). There was a lower intrafamilial transmission rate of HBV in patients with hepatitis D virus (HDV) co-infection, being statistically significant between patients positive and negative for anti-HDV antibody. This was most pronounced for HBeAg-negative female index cases, where the frequency of transmission was only 5% in those who were anti-HDV-positive compared to 25% in anti-HDV-negative females [93] . A number of factors can influence the interaction of HBV and HDV including HBV genotype. Interference of HBV replication by HDV was more apparent in patients infected with HBV genotype A compared to those infected with genotypes D or E [94] . The prevalence and characteristics of HDV infection in the pediatric population have not been widely researched.
MODES OF TRANSMISSION OF HBV IN CHILDREN
Children can be infected ante-natally, peri-natally or horizontally. Mother-to-child transmission (MTCT) can occur by all three modes:
(1) Ante-natal transmission or infection in utero occurs in the third trimester of pregnancy possibly when HBV, from maternal blood, traverses the placenta or as a result of placental leakages, infects the foetus [27, 95] . The presence of HBV in placental villous capillary endothelial cells [96] and trophoblastic cells [97] implicates "cellular transfer" of HBV from mother to foetus. This intrauterine transmission, occurs infrequently and accounts for <5% of MTCTs from HBsAgpositive, HBeAg-positive mothers [29] . Maternal blood levels of HBV DNA of >10 8 copies/ml [97] and HBeAg-positivity [96] were shown to be a risk factors for intrauterine transmission of HBV. Moreover, a direct correlation between maternal HBV DNA levels and those in cord blood exists [97] . The administration of hepatitis B immune globulin (HBIg) from 28 weeks gestation onwards reduced this risk of transmission [98] . However, this mode of transmission cannot be prevented by the administration of both HBIg and vaccine after birth [99] . (2) Perinatal transmission occurs at or near the time of delivery (28 weeks of gestation up to 7 days after birth) by percutaneous and/or permucosal exposure to maternally infected fluids in the birth canal [100, 101] . HBsAg has been detected in 33% of amniotic fluid samples, 50% of cord blood samples, 98% of vaginal fluid samples, 71% of breast milk samples and 295 HBV genotypes and HBeAg in pediatrics 95.3% of samples of gastric contents from newborns [102] . However, only a minority of amniotic fluid and cord blood samples were shown to be HBV DNA-positive [103] . Perinatal transmission is the major mode of transmission in geographical regions where there is a high frequency of HBeAg-positivity in females at gestational age. HBeAg is associated with higher viral loads and acts as a tolerogen and immunogen [20, 21] ; thus, 70% to 90% of babies born to HBeAg-positive mothers will become chronic carriers of the virus within 3 months of birth [104] [105] [106] [107] [108] [109] [110] . In contrast, chronic infection occurs in only 10% of babies born to mothers who are HBeAg-negative [111] . (3) Post-natal or horizontal transmission occurs parenterally via apparent or inapparent percutaneous or permucosal exposure to bodily fluids [35] . In addition to blood, saliva, urine and semenal fluid have also been implicated in transmission of HBV [112] . Horizontal transmission can be intra-and inter-familial [113] , iatrogenic, by the indiscriminate use of injections with non-sterilized equipment and as a result of cultural practices, including scarification and tattooing [40, 114, 115] . MTCT can occur during childcare activities including breastfeeding [116] , although no difference was noted between transmission from HBsAg-positive mothers to infants that were breast-fed compared to those that were bottle-fed [102] . Children infected perinatally can be a source of infection for siblings and playmates [116] [117] [118] [119] . The risk of infection among children increases with age [113] . The behaviors implicated in intra-familial transmission include sharing of bath towels, sharing of chewing gum or partially eaten sweets, sharing of toothbrushes and biting of fingernails in conjunction with scratching the backs of carriers [113] . HBV exposure during childhood can lead to a large proportion of adolescents being infected by the time they reach the age of sexual maturity, when sexual transmission becomes the dominant route of transmission [120, 121] . In low incidence regions of HBV, transmission mainly occurs horizontally, iatrogenically in health care personnel, drug addicts and by sexual contact in heterosexual couples or men-who-havesex-with men [116] .
THE INFLUENCE OF GENOTYPES AND SUBGENOTYPES ON MODE OF TRANSMISSION
HBV is classified in at least nine genotypes and at least 35 subgenotypes, which can have distinct geographical distributions. The different (sub) genotypes can develop various mutations that can affect HBeAg expression, which can determine the dominant mode of transmission and natural history of infection depending on the frequency of HBeAg-positivity in a population. Even before (sub) genotypes were defined and their geographical distribution well known, it was recognized that the frequency and mode of transmission of HBV varied in the different ethnic groups around the world and that these were influenced by the frequency of HBeAg-positivity [107] . A German study showed that three times as many west Asian HBsAg-positive carriers were HBeAg-positive compared to those of European descent [122] . Similarly, Chinese mothers in Singapore and Malaysia were more likely to be HBeAgpositive compared to either Indian or Malay mothers [123, 124] . A higher percentage of HBsAgpositive mothers were HBeAg-positive and had higher viraemia in south east Asia (40%) compared to mothers in Africa (5%) [125] . MTCT occurs in 40%-64% Chinese mother-infant pairs, but only in 30% and 10% of their African and European counterparts, respectively [25, 126] . Differences can also be observed within a single locale and is dependent on ethnicity. In a study carried out in Thrace, Greece, children of Turkish descent were more likely to be infected peri-natally (61.8%) compared to native Greek children (39%) and immigrant children from the former Union of Soviet Socialist Republic (USSR) (22%), who were infected by percutaneous exposure [127] . Horizontal MTCT occurs frequently in the Chinese at 6 weeks to 3 months after birth [128, 129] , whereas in other regions such as Senegal [130] and Saudi Arabia [131] transmission occurs later in infancy and childhood. Thus perinatal MTCT can account for 50% of chronic infections in endemic regions of Asia and the Pacific Islands [46] whereas it is less frequent in Africa, the other geographical region, where HBV is endemic and horizontal transmission dominates [40] .
Today we know that these differences can be accounted for because of the distribution of different (sub) genotypes in the various ethnic groups and geographical regions (Figure 7) . In south east Asia, the prevalent genotypes are B and C and HBeAg to anti-HBe seroconversion, in 90% of carriers of these genotypes, occurs at the mean age of 30-35 years [132] [133] [134] . Thus women of gestational age are frequently HBeAg-positive, have high viral loads and consequently MTCT is frequent [87, 90] . On the other hand, in Africa where the prevalent genotypes are subgenotype A1, genotypes D and E [40], carriers of these genotypes seroconvert earlier than the average gestational age. Thus MTCT occurs infrequently in less than 10% of the cases [135] [136] [137] [138] [139] , but also associated with HBeAgpositivity and high viral loads [136] .
THE INFLUENCE OF GENOTYPES AND SUBGENOTYPES ON THE NATURAL HISTORY OF HBV INFECTION IN CHILDREN
The few studies that have looked at the natural history of HBV infection in children have demonstrated geographical variations that can also be attributed to the different distributions of (sub) genotypes and their influence of HBeAg expression.
Taiwanese children of mothers, who were older than 40 years when they lost HBeAg, had delayed HBeAg seroconversion [140] . The presence of maternal HBeAg but not HBsAg at birth, delayed the children's HBeAg seroconversion significantly and this delay was enhanced when maternal HBeAg persisted [140] .
HBeAg expression also determines whether acute HBV infection develops into a chronic infection; thus, a necessary prerequisite is that the strains of HBV infecting an individual express HBeAg and thus have a wild-type BCP/PC region [25, 141, 142] . Wild-type at position 1896 of the precore region is the strongest predictor of MTCT in mothers infected with genotype E [136] . However, transmission of strains carrying G1896A can occur perinatally [143] . Genotype C patients, compared to genotype B patients, have a delayed HBeAg seroconversion in the immune clearance phase of chronic HBV infection, which may contribute to a more progressive liver disease and more refractory response to antiviral therapy [43] .
PREVENTION OF HBV INFECTION AND ERADICATION OF HBV
Since the early 1980s, there has been a successful vaccine against HBV, which can prevent HBV infection by eliciting an immune response in 95% of vaccinees [144] . The success of this vaccine was first demonstrated in Taiwan, which was one of the first countries to implement universal vaccination. HBsAg carrier rates in children decreased from 10% in 1984 to <1% in 2004, with a concomitant 68% decrease of acute liver failure in infants younger than 12 months, and a 75% reduction of HCC in children aged 6 to 14 years [42, 145] . However, despite the effectiveness of this vaccine and the implementation of universal vaccination, following a recommendation by the World Health Organization (WHO) in the early 1990s, in over 184 countries, eradication of HBV is still not on the horizon.
To reduce MTCT the WHO recommends administration of both the vaccine and HBIg within 24 h of birth, which reduce transmission by 90% -98% [1] . Children of HBeAg-positive mothers are at greater risk of developing chronic hepatitis even after immunization [146] , and although administration of HBIg born to HBeAg-negative mothers did not reduce the rate of chronic hepatitis, it can prevent infantile acute liver failure [146] .
Active and passive immunoprophylaxis in children cannot prevent MTCT in 10% of children [147] . The reasons for this outcome include:
(1) Vaccination failure, often as a result of (a) incomplete or delayed vaccination [148] (b) high HBV DNA levels in mothers leading to in utero transmission. (c) Vaccine escape mutations [148] (d) Low response to vaccine and/or waning anti-HBs levels [149, 150] 
(2) Occult infection
Occult HBV infection is defined as the presence of HBV DNA in the liver (with and without HBV DNA detected in the serum) in HBsAg-negative individuals [151] (3) Reactivation of HBV infection, often as a result of immunosuppression. (4) Immigration into countries with low HBsAg prevalence, where universal vaccination has not been implemented. This has led to a change in the epidemiological profile, with the prevalence of HBsAg, HBeAg and the genotype of HBV in immigrant children reflecting that of their country of origin [62, 152] .
refugee crisis, will result in the change of the geographical distribution of HBV genotypes and subgenotypes and a concomitant change in the natural history of HBV infection in different regions. Considering that the (sub) genotypes can affect the frequency and rate of HBeAg seroconversion, knowledge of the (sub) genotypes circulating in a region, as well as the mutations found in strains from infected children, can inform on better prevention, management and treatment options, which can be customized to a certain degree. In order be effectively manage HBV infection and to respond to the call of the inaugural World Hepatitis Summit of September 2015 [153] , for the global eradication of HBV by 2030, it is necessary that pediatricians understand the natural history of the infection, particularly the course of spontaneous HBeAg seroconversion.
A priority for all pediatricians and maternity service providers should be the implementation of the prevention recommendations of the WHO for all neonates to receive the first dose of hepatitis B vaccine within 24 h of birth. This is essential in all regions of the world, especially regions such as Africa, where HBV is still hyperendemic and vaccine coverage is not optimal. 
